ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

Bush Nominates Health Policy Advisor McClellan For FDA Commissioner

September 27, 2002

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

April 21, 2006

In Brief: $100 Million Being Spent On Interferon In U.S., Rauscher Says; DeVita; Criticism Deserved

April 4, 1980

HAS Authority Over Cancer Program Become Hot Issues; Fredrickson Opposes Exemption For NCI

October 29, 1976

NCI to Implement More Transparent Formula For Calculating Cancer Center Support Grants

June 11, 2014